Met, IGF1R, and other new targets in upper GI malignancies.

about

An updated review of gastric cancer in the next-generation sequencing era: insights from bench to bedside and vice versa

P2860

Q27027592-B3E57D4D-60FC-4D3E-BBF4-BE6BC6B72264

P2860

Met, IGF1R, and other new targets in upper GI malignancies.

Item

http://www.wikidata.org/entity/Q47967299

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Met, IGF1R, and other new targets in upper GI malignancies.

@en

Met, IGF1R, and other new targets in upper GI malignancies.

@nl

type

Item

label

Met, IGF1R, and other new targets in upper GI malignancies.

@en

Met, IGF1R, and other new targets in upper GI malignancies.

@nl

prefLabel

Met, IGF1R, and other new targets in upper GI malignancies.

@en

Met, IGF1R, and other new targets in upper GI malignancies.

@nl

P1476

Met, IGF1R, and other new targets in upper GI malignancies.

@en

P2093

Elizabeta C Popa

http://www.w3.org/2001/XMLSchema#string

Manish A Shah

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer

Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Cancer statistics, 2012

Structure and function of VEGF receptors

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

P2888

s11864-013-0245-5

P304

321-336

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11864-013-0245-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23873272

http://www.w3.org/2001/XMLSchema#string

Met, IGF1R, and other new targets in upper GI malignancies.

about

P2860

P2860

Met, IGF1R, and other new targets in upper GI malignancies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698